Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Evogliptin and Empagliflozin or Dapagliflozin
NCT03766724Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Plasma Concentration-Time Curve at Steady State at 4 weeks and Maximum Plasma Concentration at Steady State at 4 weeks. Started Nov 2018; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03766724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766724.